IC
ENTA icon

Innealta Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Innealta Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$208 – 634
2024
Q2 		$208 Buy
+16
New +$216 ﹤0.01% 1600

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Innealta Capital's ENTA Position: Q3 2024 in Review

Innealta Capital sold out of Enanta Pharmaceuticals (ENTA) in Q3 2024, closing a stake of 16 shares — an estimated $208 sold.

Innealta Capital first reported a position in ENTA in Q2 2024 and held it in 1 quarter. The position peaked at $208 in Q2 2024. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2024.

  • Innealta Capital reported no remaining Enanta Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 16 Enanta Pharmaceuticals shares in Q3 2024, an estimated $208.
  • Innealta Capital first reported a position in Enanta Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Enanta Pharmaceuticals position peaked at $208 in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.